FibroGen Announces Board and Executive Changes
Ticker: KYNB · Form: 8-K · Filed: Dec 16, 2024 · CIK: 921299
| Field | Detail |
|---|---|
| Company | Fibrogen Inc (KYNB) |
| Form Type | 8-K |
| Filed Date | Dec 16, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, executive-compensation
Related Tickers: FGEN
TL;DR
FibroGen's board and exec comp are changing, filing shows.
AI Summary
On December 16, 2024, FibroGen, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates the departure of certain officers and directors, alongside the election of new ones, and adjustments to compensatory arrangements for key executives.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategy, governance, or financial outlook, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can sometimes precede significant strategic shifts or indicate internal challenges.
Key Players & Entities
- FibroGen, Inc. (company) — Registrant
- December 16, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 350 Bay Street Suite 100 #6009 (address) — Principal Executive Offices
- San Francisco, California (location) — Principal Executive Offices City and State
- 94133 (zip_code) — Principal Executive Offices Zip Code
- 415-978-1200 (phone_number) — Registrant's Telephone Number
FAQ
What specific items are covered in this 8-K filing by FibroGen, Inc.?
This 8-K filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
On what date was the earliest event reported in this filing?
The earliest event reported in this filing was on December 16, 2024.
What is FibroGen, Inc.'s state of incorporation?
FibroGen, Inc. is incorporated in Delaware.
What is the principal executive office address for FibroGen, Inc.?
The principal executive office address for FibroGen, Inc. is 350 Bay Street Suite 100 #6009, San Francisco, California 94133.
What is the telephone number for FibroGen, Inc.?
The telephone number for FibroGen, Inc., including area code, is 415-978-1200.
Filing Stats: 1,114 words · 4 min read · ~4 pages · Grade level 12.6 · Accepted 2024-12-16 09:15:19
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value FGEN The Nasdaq Global Se
Filing Documents
- fgen-20241216.htm (8-K) — 56KB
- fgen-ex99_1.htm (EX-99.1) — 13KB
- img3914235_0.jpg (GRAPHIC) — 11KB
- img3914235_1.jpg (GRAPHIC) — 2KB
- 0000950170-24-136408.txt ( ) — 235KB
- fgen-20241216.xsd (EX-101.SCH) — 43KB
- fgen-20241216_htm.xml (XML) — 6KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release titled "FibroGen Appoints David DeLucia as Chief Financial Officer" dated December 16, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FIBROGEN, INC. Date: December 16, 2024 By: /s/ John Alden John Alden VP, Legal